https://www.zacks.com/stock/news/2212386/maia-soars-20-on-interim-results-from-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212386
Jan 18, 2024 - MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.
zc:-5634115568131083711
0
https://www.zacks.com/stock/news/2212339/novo-nordisk-nvo-upgraded-to-strong-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2212339
Jan 18, 2024 - Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zc:6987688662634361821
0
https://www.zacks.com/stock/news/2212144/why-novo-nordisk-nvo-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2212144
Jan 18, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zc:8823690833943782744
0
https://www.zacks.com/commentary/2210722/best-growth-stocks-to-buy-for-january-16th?cid=CS-ZC-FT-zacks_1_rank_additions|growth_additions-2210722
Jan 16, 2024 - NVO, AIZ and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 16, 2024.
zc:-6055156714187085844
0
https://www.zacks.com/stock/news/2210387/here-is-why-growth-investors-should-buy-novo-nordisk-nvo-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-2210387
Jan 15, 2024 - Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
zc:-9089560703886464258
0
https://www.zacks.com/stock/news/2210353/novo-nordisk-nvo-is-up-2-45-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2210353
Jan 15, 2024 - Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
zc:7381955471840593899
0
https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152
Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
zc:5632938074738624243
0
https://www.zacks.com/stock/news/2209723/unitedhealth-group-unh-q4-earnings-beat-on-membership-growth?cid=CS-ZC-FT-analyst_blog|earnings_article-2209723
Jan 12, 2024 - UnitedHealth Group's (UNH) Q4 results benefit on the back of double-digit revenue growth in its UnitedHealthcare and Optum segments. Management maintains its 2024 adjusted EPS target within $27.50-$28.00.
zc:3348874277659739299
0
https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-235-8m-dod-contract-for-anthrax-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209718
Jan 12, 2024 - Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
zc:848950683659506592
0
https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209026
Jan 11, 2024 - The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
zc:-5547571457753162198
0